Clinical Trials Logo

Filter by:
NCT ID: NCT05932121 Recruiting - Thyroid Cancer Clinical Trials

Cross-sectional Case and Control Study on Quality of Life, Appearance and Functions in PTC Via Different Surgical Approach

Start date: June 25, 2023
Phase:
Study type: Observational

An observational cross-sectional case-control study on the postoperative quality of life (5 aspects, general quality of life, thyroid specific quality of life, scar appearance, voice and swallowing functions) of papillary thyroid carcinoma (PTC) patients underwent thyroid lobectomy via different approach, open vs trans-axillary. The patients are recruited in Peking Union Medical College Hospital (PUMCH) from 2020 to 2023 and are evaluated by follow-up with both outpatient visits and questionnaires made up of 9 validated scales.

NCT ID: NCT05932095 Recruiting - Anxiety State Clinical Trials

TCM Daoyin in the Treatment of Patients With Anxiety State

Start date: June 13, 2023
Phase: N/A
Study type: Interventional

In recent years, the number of people with symptoms of anxiety are on the rise. TCM Daoyin is a promising intervention for anxiety. This study is designed to allow researchers to better understand the changes in anxiety symptom, brain activity, and immune function during patients with anxiety states receiving TCM Daoyin intervention. Thus, the aims of the prospective randomized study are: (1) to examine the effects of TCM Daoyin training on reducing symptoms of anxiety, (2) to measure brain activity by using functional magnetic resonance imaging (fMRI), and (3) to assess Immune function.

NCT ID: NCT05931328 Recruiting - Clinical trials for Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma

The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

Start date: October 15, 2022
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the efficacy and safety of the combination of thiotepa and pomalidomide in the treatment of relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL).

NCT ID: NCT05931263 Recruiting - Clinical trials for Newly Diagnosed Peripheral T-cell Lymphoma

A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL. The main question it aims to answer are: •Whether Chi-BEAM improves patient survival compared to BEAM group Participants will be given BEAM or Chi-BEAM before ASCT. Researchers will compare the efficacy and safety of the two groups.

NCT ID: NCT05930717 Recruiting - Clinical trials for Cardiovascular Diseases

Zhejiang Nutrition and Health Study

NuLife
Start date: July 19, 2023
Phase:
Study type: Observational

This project aims to explore the relationship between healthy lifespan and nutrition through a 10-year longitudinal study in Zhejiang Province. The cohort will include individuals in a wide range of age groups. The demographic, diet, lifestyle information, health status, and corresponding bio-samples will be collected carefully. It will give a deeper insight to the relation between nutrition and healthy aging and longevity. Ultimately, this research will contribute to evidence-based nutrition interventions to improve health outcomes and enhance quality of life.

NCT ID: NCT05930704 Recruiting - Osteoporosis Clinical Trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women

Start date: July 4, 2023
Phase: Phase 1
Study type: Interventional

The primary objective was to evaluate the safety and tolerability of SHR-2017 after a single subcutaneous (SC) injection in postmenopausal women

NCT ID: NCT05930665 Recruiting - Clinical trials for Pleural Mesothelioma

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Start date: November 1, 2023
Phase: Phase 2
Study type: Interventional

Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.

NCT ID: NCT05930405 Recruiting - Clinical trials for Video-assisted Thoracic Surgery

Effect of the PIEB Versus CEI on the Quality of Postoperative Recovery in Patients Undergoing VATS Lobectomy

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

In recent years, lobectomy under VATS(Video-assisted thoracic surgery,VATS) has gradually emerged, but there is still a proportion of patients with postoperative pain that affects their postoperative recovery. Epidural analgesia (EA) , the gold standard for postoperative analgesia in thoracic surgery, is currently administered in two ways: 1) continuous epidural infusion 2) programmed intermittent epidural bolus. The former is currently the commonly used method of anesthetic infusion, while the latter has been better studied in obstetrics and major abdominal surgery, but is still unclear in thoracic medicine. This paper aims to investigate the impact of both drug delivery methods on the quality of postoperative recovery in patients undergoing lobectomy by VATS.

NCT ID: NCT05930301 Recruiting - Cervical Clinical Trials

RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)

Start date: October 1, 2021
Phase:
Study type: Observational

This clinical study will include tumor patients in strict accordance with the inclusion and exclusion criteria set in this clinical study, and carry out tumor-specific antigen screening, HLA typing, blood sample collection, cell separation, cell culture and cell reinfusion according to the SOP of Suzhou Ruotai RT201 Cell Therapy. According to the efficacy evaluation criteria set in this clinical study, the included patients will be evaluated and followed up for a long time, and the original data will be saved to provide real and effective clinical data for the safety and efficacy of RT201 tumor single-target individualized clinical treatment.

NCT ID: NCT05930275 Recruiting - Crohn's Disease Clinical Trials

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

UPlift
Start date: February 19, 2024
Phase:
Study type: Observational

Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world. Speed of onset and durability of effectiveness will be assessed. Upadacitinib is a drug approved for the treatment of CD. All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 1200 participants will be enrolled in approximately 230 sites across the world. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.